Non-estrogen-based therapies can be used for the treatment of hot flushes, for symptoms of urogenital atrophy and for lack of sexual desire and/or fatigue not improved by estrogen treatments. Treatment choice should be based on up-to-date information and targeted to individual women’s needs. Non-hormonal therapies are useful particularly for women with estrogen-dependent disease such as breast and endometrial cancers.
RadaGCapurroDPantojaT. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev2010; 9: CD004923.
2.
LammerinkEAde BockGHSchröderCP. The management of menopausal symptoms in breast cancer survivors: case-based approach. Maturitas2012; 73: 265–268.
3.
SiderasKLoprinziCL. Nonhormonal management of hot flashes for women on risk reduction therapy. J Natl Compr Canc Netw2010; 8: 1171–1179.
4.
FreemanGSamuelMLinH. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol2011; 117: 1095–1104.
5.
SassariniJLumsdenMA. Non-hormonal management of vasomotor symptoms. Climacteric2013; 16(Suppl 1): 31–36.
6.
CarrollDGKelleyKW. Use of antidepressants for management of hot flashes. Pharmacotherapy2009; 29: 1357–1374.
7.
NelsonHVescoKHaneyE. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA2006; 295: 2057–2071.
8.
Suvanto-LuukkonenEKoivunenRSundstromH. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomised, 9 month, placebo controlled, double blind study. Menopause2005; 12: 18–26.
9.
KalayAEDemirBHaberalA. Efficacy of citalopram on climacteric symptoms. Menopause2007; 14: 223–229.
10.
LaCroixAZFreemanEWLarsonJ. Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial. Maturitas2012; 73: 361–368.
11.
EnsrudKEJoffeHGuthrieKA. Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial. Menopause2012; 19: 848–855.
12.
FreemanEWGuthrieKACaanB. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA2011; 305: 267–274.
13.
JinYDestaZStearnsV. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst2005; 97: 30–39.
14.
LashTLCronin-FentonDAhernTP. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol2010; 49: 305–312.
15.
L'EspéranceSFrenetteSDionneA. Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer2013; 21: 1461–1474.
LoprinziCLKuglerJWSloanJA. Venlafaxine in the management of hot flashes in survivors of breast cancer: a randomised, controlled trial. Lancet2000; 356: 2059–2063.
18.
EvamsMLPrittsEVittinghoffE. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomised, controlled trial. Obstet Gynecol2005; 105: 161–166.
19.
SperoffLGassMConstantineG. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomised controlled trail. Obstet Gynecol2008; 111: 77–87.
20.
PandyaKJMorrowGRRoscoeJA. Gabapentin for hot flashes in 420 women with breast cancer: a double-blind placebo controlled trial. Lancet2005; 366: 818–824.
21.
PopATannaNPitkinJ. Breast cancer patient case study – prescribing of gabapentin for vasomotor symptom control and supporting patient compliance/concordance. Maturitas2009; 63: S53.
22.
LoprinziCLQinRBalcuevaEP. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol2010; 28: 641–647.
PandyaKJRaubertasRFFlynnPJ. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flushes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med2000; 132: 788–793.
KingsbergSAWysockiSMagnusL. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med2013; 10: 1790–1799.
27.
SinhaAEwiesAA. Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview. Climacteric2013; 16: 305–312.
28.
BaumgartJNilssonKEversAS. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause2013; 20: 162–168.
29.
LindauSTSchummLPLaumannEO. A study of sexuality and health among older adults in the United States. N Engl J Med2007; 357: 762–774.
30.
Tomlinson JM, Rees M and Mander T (eds). Sexual health and the menopause. London: RSM Press and British Menopause Society Publications, 2005.
31.
WylieKR. Sexuality and the menopause. J Br Men Soc2006; 12: 149–152.
32.
DavisSRvan der MoorenMJvan LunsenRH. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomised, placebo controlled trail. Menopause2006; 13: 387–396.
33.
BraunsteinGDSundwellDAKatzM. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomised, placebo controlled trial. Arch Intern Med2005; 165: 1582–1589.
34.
SimonJBraunsteinGNachtigallL. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab2005; 90: 5226–5233.
35.
ShifrenJLDavisSRMoreauM. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NMI study. Menopause2006; 13: 770–779.
